With the long-term aim of narrowing the gap on market leader Gilead Sciences, GlaxoSmithKline’s HIV unit ViiV Healthcare, which is minority owned by Pfizer and Shionogi, has agreed to acquire Bristol-Myers Squibb’s clinical-stage and early-stage HIV assets via two separate deals together worth almost US$3 B. ViiV will gain a number of potentially first-in-class therapeutics such as the HIV-1 attachment inhibitor fostemsavir, which is currently in Phase III development with regulatory filings expected in 2018.